Drug safety is a serious concern in the United States with adverse drug events contributing to over 770,000 injuries and deaths per year. Cost estimates range from $1.5 to $5.6 billion annually. The FDA closely monitors these adverse events and releases communications and advisories depending on the severity and frequency of the events. The FDA released such a communication regarding the drug Simvastatin in June 2011. Simvastatin, which is used to treat hyperlidemia, is one of the most heavily prescribed medications in the world, and nearly 100 million prescriptions were written for patients in 2010.
This demonstration draws on data from the FDA, Practice Fusion, and the National Library of Medicine to uncover how a drug communication can efficiently be applied to electronic medical records (EMR) within a health network. Through a variety of techniques, at-risk patients can be quickly found and notified using the Palantir platform.